This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 1998 Nov 14;352(9140):1567-8.

doi: 10.1016/S0140-6736(05)61037-9.

Platinum alone for chemotherapy for ovarian cancer?

C Johnston¹

Affiliations

PMID: 9843097
DOI: 10.1016/S0140-6736(05)61037-9

Comment

Platinum alone for chemotherapy for ovarian cancer?

C Johnston. Lancet. 1998.

. 1998 Nov 14;352(9140):1567-8.

doi: 10.1016/S0140-6736(05)61037-9.

Author

C Johnston¹

Affiliation

¹ Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor 48109, USA.

PMID: 9843097
DOI: 10.1016/S0140-6736(05)61037-9

No abstract available

PubMed Disclaimer

Comment on

ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.
[No authors listed] [No authors listed] Lancet. 1998 Nov 14;352(9140):1571-6. Lancet. 1998. PMID: 9843101 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information